Truenat, a real-time PCR platform for testing people infected with Nipah virus, is being graded emergency authorization for use by the Drugs Controller General of India (DCGI). Truenat is the first kit in the country to receive regulatory approval to conduct tests for Nipah. It is manufactured by Goa-based Molbio Diagnostics.
Truenat is a portable battery-operated, RT-PCR platform developed. The kit can test nearly 30 diseases and the results take less than an hour. It is already playing a critical role in the management of diseases like dengue, TB, COVID-19, chikungunya, hepatitis, and HPV in India.
Sriram Natarajan, the CEO and director of the Molbio Diagnostics said, "COVID-19 has brought out the importance of early and accurate testing for better disease management. Truenat is the first platform to be authorised by the DCGI for Nipah virus testing. We are proud to support our country in fighting the Nipah Virus."
The research and development work of the kit was first started by the company for Nipah virus in 2018 along with the National Institute of Virology, Pune.
The kitis also approved by the WHO for TB diagnosis. ICMR has also given green for TB, COVID-19 and other diseases.